Aaron Ciechanover is a Distinguished Research Professor at the Technion—Israel Institute of Technology who received the 2004 Nobel Prize in Chemistry, together with Avram Hershko and Irwin Rose, for the discovery of ubiquitin-mediated protein degradation. The ubiquitin-proteasome system (UPS) is a critical cellular mechanism for tagging damaged, misfolded, or regulatory proteins for destruction by the proteasome. Ciechanover's elucidation of this system—particularly the enzymatic cascade (E1, E2, E3 ligases) responsible for polyubiquitin chain attachment—has had profound implications for understanding cancer, neurodegeneration, and immune function. The UPS is now one of the most intensively drugged pathways in oncology; proteasome inhibitors like bortezomib and carfilzomib are mainstays of multiple myeloma therapy. Ciechanover actively advocates for the next generation of UPS-targeting drugs, including PROTACs (proteolysis-targeting chimeras), which use the UPS to degrade disease-causing proteins. His foundational science underpins the multi-billion dollar proteasome inhibitor market and the emerging PROTAC drug modality.